BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32162184)

  • 21. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
    Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
    J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
    Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
    Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
    Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and Management of Hereditary Thyroid Cancer.
    Bano G; Hodgson S
    Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial non-medullary thyroid cancer: a critical review.
    Capezzone M; Robenshtok E; Cantara S; Castagna MG
    J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Analysis of Familial Nonmedullary Thyroid Carcinoma.
    Zhang Q; Yang S; Meng XY; Chen G; Pang RZ
    World J Surg; 2016 Mar; 40(3):570-3. PubMed ID: 26711636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.
    Uchino S; Noguchi S; Kawamoto H; Yamashita H; Watanabe S; Yamashita H; Shuto S
    World J Surg; 2002 Aug; 26(8):897-902. PubMed ID: 11965446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis.
    Wang X; Cheng W; Li J; Su A; Wei T; Liu F; Zhu J
    Eur J Endocrinol; 2015 Jun; 172(6):R253-62. PubMed ID: 25637073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma.
    de Carlos Artajo J; Irigaray Echarri A; García Torres J; Pineda Arribas JJ; Ernaga Lorea A; Eguílaz Esparza N; Zubiría Gortázar JM; Anda Apiñániz E
    Endocrinol Diabetes Nutr (Engl Ed); 2022 Apr; 69(4):262-270. PubMed ID: 35353680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial nonmedullary thyroid cancer.
    Sturgeon C; Clark OH
    Thyroid; 2005 Jun; 15(6):588-93. PubMed ID: 16029126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
    Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
    Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic aspects of familial thyroid cancer.
    Morrison PJ; Atkinson AB
    Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
    Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
    Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
    de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
    Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial nonmedullary thyroid carcinoma.
    Malchoff CD; Malchoff DM
    Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
    Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.